Home - Products - Others - Other Targets - p-Hydroxybenzaldehyde glucoside

p-Hydroxybenzaldehyde glucoside

CAS No. 26993-16-8

p-Hydroxybenzaldehyde glucoside( —— )

Catalog No. M37782 CAS No. 26993-16-8

p-Hydroxybenzaldehyde glucoside (4-formylphenyl b-d-glucopyranoside) is an inhibitory aspergillus derivative with analgesic activity and can be used to study neurogenic pain.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
1 mL x 10 mM in DMSO	89	In Stock
2MG	55	In Stock
5MG	93	In Stock
10MG	147	In Stock
25MG	296	In Stock
50MG	431	In Stock
100MG	621	In Stock
200MG	868	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

p-Hydroxybenzaldehyde glucoside
Note

Research use only, not for human use.
Brief Description

p-Hydroxybenzaldehyde glucoside (4-formylphenyl b-d-glucopyranoside) is an inhibitory aspergillus derivative with analgesic activity and can be used to study neurogenic pain.
Description

p-Hydroxybenzaldehyde glucoside (4-formylphenyl b-d-glucopyranoside) is an inhibitory aspergillus derivative with analgesic activity and can be used to study neurogenic pain.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

Others
Research Area

——
Indication

——

Chemical Information

CAS Number

26993-16-8
Formula Weight

284.26
Molecular Formula

C13H16O7
Purity

>98% (HPLC)
Solubility

——
SMILES

OC[C@H]1O[C@@H](Oc2ccc(C=O)cc2)[C@H](O)[C@@H](O)[C@@H]1O
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

Homoembelin

Homoembelin, a pigment from E. ribes and C. monocarpus, is an antibacterial compound that has the potential to study multidrug-resistant bacterial infections.
IMP-1088

IMP-1088 is a potent inhibitor of human N-myristoyltransferases NMT1 and NMT2 dual.
Linzagolix

Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis.

Sign In Join Free